Grace Wong's profile
What I do
Dr Grace Wong, CSO, ActoKine Therapeutics
Dr. Grace Wong has worked for Genentech, Millennium, AstraZeneca and Serono on new drug discovery in a variety of therapeutic areas. Dr. Wong earned a PhD at The Walter and Eliza Hall Institute of Medical Research in Australia. Dr. Wong did a postdoc with Dr. David Goeddel at Genentech and advanced basic research discoveries to product development. In 1996, Dr. Wong became the Head of Apoptosis Research at Millennium Pharmaceuticals, worked at AstraZeneca as Section Head of Molecular Genetics and at Serono as Head of Functional Genomics. She has been awarded 13 scholarships from Australian and American organizations and received 5 Recognition Awards from Genentech.
Dr. Wong has been invited to give presentations at 153 international conferences including the Nobel Symposium (Sweden, 1994). She has published 93 papers and filed 28 patents. Some of her publications (3 Nature, 1 Science, 3 Cell, 5 PNAS, and 7 J. Immunol) have received 300-1000 citations.
Dr. Wong has founded Actokine Therapeutics for new drug advancements for cancer, obesity, CNS and emerging viral diseases. She also founded Student Vision and the Nobel Pauling Symposia to help scientists of all ages in biotechnology.
Affiliations
Current affiliations
-
- Position
- Chief Scientific Officer & President
- Company
- ActoKineTherapeutics
- Further information
Location
- City:
- None chosen
- Hub:
- Boston
Interests
New drug discovery (loves working in the lab)
Aerobic dancing, Chinese drawing, playing chinese musics, loves eating and learning,
Gardening, giving seminars for students ” career decision: academia vs Industry”
Organizing Nobel Pauling Symposium (Biotech Pow-Wow) even on thanksgiving day and Christmas.
Enjoy helping build a biotech bridge between academia and industry and between USA, Europe, Australia and Asia.
Very interested to mix good business, education with exciting science globally.
Enjoy writing articles to inspire students in biotechnology (see below).
Get a Foot in the Door, 431, 1128, Nature
Consider post-doctoral training in industry, 23, 151 – 152 (2005) Nature Biotech
Ask the experts: How to get Hired. Nov 2004, 22, 1481 – 1482 (2004) Nature Biotech
The best preparation for a scientist job search, 23, 265 – 265 (2005) Nature Biotech
Five attributes of a successful manager in a research organization, 24, 1171 – 1174 (2006) Nature
Chinese biotech: the need for innovation and higher standards, 24, 221 – 222 (2006) Nature biotech
Projects
Identification of Biomarkers inducible by AK-1 for radioprotection, AK-2 for protection against a broad spectrum of viral infections and AK-3 for obesity
Grace Wong PhD, Chief Scientific Officer, ActoKine Therapeutics, grace@actokine.com, Boston
Viral infection is a key mechanism of human diseases, and with the emerging threats of pandemic diseases and bio-terrorism, the means to control and prevent viral infections are of immediate importance. We propose a novel strategy to provide a broad anti-viral prophylaxis.
ActoKine Therapeutics has identified ActoKine-2 (AK-2), which can protect cells against a broad spectrum of virus infections. AK-2 has been shown to be more potent, effective and protective than interferons against different virus infection. Actokine is collaborating with NIAID and different laboratories and has found that AK-2 is very active against a variety of viruses in vitro and in vivo.
ActoKine has also identified AK-1 that protects stem cells against radiation damage and AK-3 for obesity. ActoKine’s proprietary technologies (CytoKey and CytoKill) will enable discovery and validation of the function of the master control genes and biomarkers which will allow for screening for AK-1, AK-2 or AK-3 mimetics among small molecule drug candidates for cancer and virus prevention.
Publications
Grace Wong has listed no publications on Nature Network.
Grace Wong's activity on Nature Network
Entries
There are no recent entries from Grace Wong.
Network
Grace Wong's network is currently empty.
Groups
Grace Wong hasn't joined any groups yet.